Ionis Pharmaceuticals Inc
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
426 / 1361
Position in country
7291 / 14179
Return on Assets, %
-12.9
-40.3
Net income margin, %
-2.9
-180
EBITDA margin, %
-1
-168.2
Debt to Equity, %
329.6
3.2
Intangible assets and goodwill, %
0
0.2
Revenue CAGR 3Y, %
2.6
12.5
Total Equity change 1Y, %
-32.6
-9
Revenue Y, % chg
34
0
P/BV
15.5
1.8
P/S
7.7
10.3
EV/S
6.3
7.5
EV/EBITDA
-18.2
-1.6
Average Analyst recommendation
Hold
Hold
Average upside forecasts, %
38.9
131.1
Expected dividend per share
0
0
Competitors
Ranks
-
Vertex Pharmaceuticals Inc
00%
-
Regeneron Pharmaceuticals Inc
00%
-
Gilead Sciences Inc
00%
-
Seagen Inc
00%
-
Amgen Inc
00%
-
Ionis Pharmaceuticals Inc
00%
-
Moderna Inc
00%
-
Alnylam Pharmaceuticals Inc
00%
-
AbbVie Inc
00%
-
Biogen Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
United States of America
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Sub-sector
Health Care
Capitalization (millions of $)
6083.6
Ticker
IONS.O
ISIN
US4622221004
IPO date
1991-05-17
Availability on Russian exchanges
Yes
Reporting for
2024-02-21
Date fact. publication of reports
2023-12-31
Company Description
Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company is primarily focused on two core franchises: neurology and cardiometabolic. Its products include SPINRAZA, TEGSEDI and WAYLIVRA. SPINRAZA is for treatment of patients of all ages with spinal muscular atrophy (SMA), a progressive, debilitating and often fatal genetic disease. TEGSEDI is for the treatment of patients with polyneuropathy caused by hereditary transthyretin (TTR), amyloidosis (hATTR), a debilitating, progressive, and fatal disease. Its products in pipeline include tofersen for SOD1-ALS, eplontersen (IONIS-TTR-LRX) for TTR, IONIS-APOCIII-LRx for familial chylomicronemia syndrome (FCS), pelacarsen for lipoprotein(a) (Lp), driven cardiovascular disease and ION363 for amyotrophic lateral sclerosis (ALS), with mutations in the fused in sarcoma gene (FUS).
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: